Coronavirus Update: Gilead To Meet Global Remdesivir Demand By October

Plus: AstraZeneca Signs China Vaccine Deal

Ramp-up is possible thanks to increased internal capacity and network of voluntary licensing partners including Mylan, Cipla and Dr Reddy's.  

Laboratory
A COVID-19 testing laboratory in Madrid, Spain.

Gilead Sciences, Inc. has confirmed that it will be able to meet global demand for its COVID-19 antiviral therapy remdesivir by October, thanks to a rapid ramp up in its manufacturing capacity.

The US company has been investing in its own manufacturing capacity since before the US Food and Drug Administration gave...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip